Latest News - Boston Scientific
Top Corporates Hub
Boston Scientific
Boston Scientific stock tumbles 6% after guidance cut
27.05.2026 13:46
Investing.com -- Boston Scientific Corp (NYSE:BSX) fell over 6% Wednesday after management lowered its full-year guidance during a presentation at Bernstein.
Boston Scientific Recalls Test Cardiac Device Quality And Investor Confidence
26.05.2026 06:07
Boston Scientific (NYSE:BSX) has initiated two voluntary recalls of its LUX-Dx II arrhythmia detector and alarm devices. The recalls follow FDA enforcement reports citing failures in data collection and monitoring of critical cardiac events for certain patients. Issues include discrepancies in device programming interfaces that affect reliability of arrhythmia monitoring and treatment decisions. The recalls are ongoing and affect patients and clinicians in multiple regions, including the US...
Why Is Boston Scientific (BSX) Down 13% Since Last Earnings Report?
22.05.2026 15:30
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG's SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
21.05.2026 12:54
ISRG's SP platform sees Q1 2026 procedures jump 68%, with new approvals and tools raising a key question: TAM expansion or procedure shift?
Boston Scientific Corp (NYSE:BSX) GARP Growth at a Reasonable Price Meets Strong Fundamentals
21.05.2026 09:40
Boston Scientific (BSX) fits a GARP strategy with solid growth, a P/E of 18.28, high profitability, and strong health ratings—ideal for balanced investors.
Jim Cramer on Globus Medical: “There Is Not a Lot of Money to Be Made in This One”
20.05.2026 18:05
Globus Medical, Inc. (NYSE:GMED) was among the stocks Jim Cramer looked at as he explained the need for a tame bond market for the stock market to go higher. A caller asked for Cramer’s thoughts on the company, and he remarked: Okay, this group in particular, the medical device group, is hated in this market. […]
Boston Scientific Trial Success Adds Weight To SEISMIQ 4CE And BSX Valuation
20.05.2026 17:06
Boston Scientific (NYSE:BSX) reported positive pivotal trial results for its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter. The FRACTURE trial met all primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The company plans to use these data to support a regulatory submission for SEISMIQ 4CE. Boston Scientific is a major player in interventional cardiology, with products focused on treating complex coronary and structural heart...
Boston Scientific Corporation (BSX) Fell Due to Weak Results
20.05.2026 13:19
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
20.05.2026 11:23
With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now. On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78. It reiterated an Outperform rating on the shares. The firm updated its model […]
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
19.05.2026 10:31
Boston Scientific Corporation (NYSE: BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well as procedural success. Findings from th
Boston Scientific invests $1.5bn for equity stake in MiRus
19.05.2026 10:22
Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.
Boston Scientific Pairs US$2b Buyback With MiRus TAVR Growth Bet
19.05.2026 01:16
Boston Scientific (NYSE:BSX) announced a US$2b accelerated share repurchase program. The company also agreed to invest US$1.5b in MiRus, securing a significant equity stake. The MiRus deal includes an exclusive option related to the company’s transcatheter aortic valve replacement (TAVR) business. Boston Scientific, a large medical device company focused on cardiovascular and other interventional therapies, is pairing a sizeable capital return with a move deeper into structural heart...
Jim Cramer on Boston Scientific: “I Think You Gotta Hold It”
14.05.2026 16:37
Boston Scientific Corporation (NYSE:BSX) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. During the lightning round, a caller asked if they should sell or buy more BSX shares. Cramer replied: I hate to sell these. I don’t mean to sound […]
Boston Scientific (BSX) Fell Amid Concerns Over Growth Durability
14.05.2026 14:26
Aristotle Capital Management, LLC, an investment management company, released its “Core Equity Fund” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. During the first quarter, the U.S. equity market declined, with the S&P 500 Index falling by 4.33%. The fixed-income sector also saw a downturn; the Bloomberg U.S. Aggregate Bond Index […]
Boston Scientific Corp (NYSE:BSX) Shines in Quality "Caviar Cruise" Screen
14.05.2026 09:30
Boston Scientific (BSX) excels in quality metrics with 34.7% EBIT growth, 30.3% ROIC, and strong cash flow. A compelling long-term investment with a P/E of 17.1, it meets Caviar Cruise criteria for durable advantages and financial discipline.
Is Boston Scientific (BSX) Quietly Recasting Its Ownership Structure To Sharpen Its Investment Story?
14.05.2026 01:12
Earlier in May 2026, Boston Scientific filed a US$565.7 million shelf registration for up to 10,000,000 common shares tied to an ESOP-related offering, while shareholders also approved charter amendments eliminating supermajority voting and adding limited officer exculpation under Delaware law. Taken together with recent director equity and deferred stock awards, these developments highlight a stronger emphasis on ownership-based incentives and refreshed corporate governance at the...
Jim Cramer Won't 'Dump' This Medical Device Maker, Passes On Ford
13.05.2026 12:01
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended holding Boston Scientific Corporation. “I don't understand how this thing could have fallen so fast,” he said of the medical device maker. “I know there's a lot of competition. I don't...
Boston Scientific Insiders Sold US$1.2m Of Shares Suggesting Hesitancy
13.05.2026 11:00
Boston Scientific Corporation ( NYSE:BSX ) shareholders might have a reason to worry after multiple insiders sold their...
[Latest] Global Flexible Endoscope Market Size/Share Worth USD 22.7 Billion by 2035 at a 6% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
11.05.2026 17:30
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Flexible Endoscope Market size & share revenue was valued at approximately USD 12.7 Billion in 2025 and is expected to reach USD 13.5 Billion in 2026 and is expected to reach around USD 22.7 Billion by 2035, at a CAGR of 6% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Olympus Corporation, Cook Medical
BSX Q1 Neuromodulation Sales Rise 15% Y/Y: What Lies Behind the Growth?
08.05.2026 15:25
Boston Scientific's Neuromodulation unit posts 15% organic sales growth in Q1, fueled by pain management gains, the acquisition of Nalu and momentum in Intracept.